// Biotech and Pharma Therapeutics
Breaking the Cycle of Inflammation in Parkinson’s Disease
July 15, 2024 / Neuroinflammation / Parkinson’s / Disease Treatment Loss
Preventing or reversing neuroinflammation could be a new clinical frontier for treating Parkinson’s disease. Companies are developing therapies targeting the inflammasome NLRP3 and proteins like GCase to halt neurodegeneration and potentially modify disease progression.
Aligning Primary Care with Behavioral Health is Critical to Patient Outcomes
July 16, 2024 /CMS Primary Care / ACO PC Flex Model / Behavioral Health
Aligning primary care with behavioral health is essential for improved patient outcomes, particularly in underserved populations. CMS’s new ACO PC Flex Model promotes integration and equitable access through innovative reimbursement structures.
What are the odds we get an heir to Paxlovid?
July 15, 2024 / Lexeo Therapeutics / Gene Therapy / Heart Disease / FDA Approval
Lexeo Therapeutics is developing a gene therapy to prevent deadly heart complications in Friedreich’s ataxia patients. Early results are promising, with potential for FDA approval following further study.
Still not over the hump, as biotech heads into 2H24
July 12, 2024 / Federal Reserve / Investment Trends
Biotech investors are optimistic about financing pipelines amid positive catalysts. However, uncertainty around the Federal Reserve’s interest rate decisions is tempering this optimism and affecting the sector’s overall risk appetite.
How Startup miRecule Leveraged Its RNA Platform Tech to Land a Sanofi Alliance
July 14, 2024 / RNA Therapy / Sanofi / Partnership / Gene Therapy / Innovation
miRecule partnered with Sanofi to develop RNA therapy for facioscapulohumeral muscular dystrophy (FSHD). Utilizing its DREAmiR platform, miRecule aims to target the DUX4 gene, with promising preclinical results and substantial funding potential.
// 4th Industrial Revolution
90% of Healthcare Insurers Struggle to Get Insights from Data – Is AI the Answer?
July 16, 2024 / Healthcare / AI / Data Challenges / Data Analysis
A study by ActiveOps highlights that 90% of healthcare insurers struggle with data insights, impeding decision-making. AI is seen as a potential solution for real-time data analysis, yet adoption is hindered by poor data quality, leadership skepticism, and job displacement fears.
How to mitigate institutional inequities involving AI
July 15, 2024 / AI / Healthcare / New Tech
Ensuring equitable AI implementation in healthcare is crucial to avoid widening disparities. Government policies, education initiatives, and collaborative models can help smaller, underfunded hospitals access AI technologies, benefiting all patients.
New AI approach optimizes antibody drugs
July 15, 2024 / AI / Antibody Optimization / Drug Development / Machine Learning
Stanford scientists developed an AI method to optimize antibody drugs by integrating protein structures with amino acid sequences, significantly improving antibody effectiveness against SARS-CoV-2. This method accelerates drug development and enhances responses to evolving diseases.
Patients less likely to seek virtual behavioral care when paying out-of-pocket
July 11, 2024 / Telemental Health / Virtual Behavioral / Mental Health
A study found that patients with high-deductible health plans are less likely to seek telemental health care when required to pay out-of-pocket. This suggests reduced mental health service use and potentially worse clinical outcomes when cost-sharing is implemented.
Use of AR, VR and AI tools across the healthcare landscape
July 12, 2024 / Healthcare Technology / AR / AI / Healthcare / Medical Training
AR, VR, and AI enhance patient experiences, outcomes, and medical training. Effective use in healthcare requires addressing patient needs and collaborative development, ensuring personalized care and early intervention, says Jess Rengstorf of Endava.
// Business & Markets
Truvian Health raises $74M for automated blood diagnostics platform
July 17, 2024 / Truvian Health / Funding / Automated Blood Diagnostics / FDA Clearance
Truvian Health raised $74 million to advance its automated blood diagnostics platform, which combines immunoassay, hematology, and clinical chemistry testing for immediate results. The funds will support FDA clearance, aiming to enhance primary care and reduce healthcare costs.
Digital Health’s Funding Rebound Is Going Well, Market Research Shows
July 15, 2024 / Digital Health / Healthcare / Startups / Funding Recovery
Digital health funding is rebounding, with global venture capital totaling $65.7 billion in Q2 2024. Deal sizes are increasing, and early-stage deals dominate. U.S. digital health startups raised $5.7 billion in H1 2024, signaling a steady market recovery.
Edward Lifesciences Acquires ARC Spinout Innovalve Bio Medical
July 10, 2024 / Flagship Pioneering Fundraising / Life Sciences / AI / Drug Discovery / Startup
Edward Lifesciences acquired Innovalve Bio Medical, a Sheba Medical Center ARC spinout developing a minimally invasive mitral valve replacement. Innovalve’s technology, approved for initial human trials, underscores ARC’s success in fostering healthcare innovation.
Story Health, Guidehealth partner to develop cardiology program
July 15, 2024 / AI / Cardiology / Telehealth / Patient Care
Story Health and Guidehealth are partnering to create a cardiology program for hospital systems, combining telehealth, AI, and value-based care to enhance patient management and outcomes while reducing costs.
Walgreens’ Finances Are in Dire Straits — But All Hope Is Not Lost
July 14, 2024 / Walgreens / Parmacy / Stock Decline
Walgreens is facing severe financial difficulties, with stock prices dropping by 80% in five years and plans to close 25% of its stores by 2027. Despite these challenges, strategic cost management and a renewed focus on core pharmacy services offer potential for recovery.
// Legal & Regulatory
FDA proposes cell and gene therapy site tours to help regulators learn from industry
July 15, 2024 / FDA / Cell Gene Therapy / Partnership
The FDA proposes facility tours for cell and gene therapy manufacturers to enhance regulatory skills and industry understanding. This program aims to share knowledge on product development and regulatory best practices, improving both regulatory review and industry processes.
Vertex sues U.S. government over access to fertility support services for Casgevy patients
July 15, 2024 / Vertex / Lawsuit / Fertility Support / CRISPR-based medicine
Vertex Pharmaceuticals filed a lawsuit against the U.S. government, challenging a decision that prevents it from funding fertility preservation services for patients receiving Casgevy, a CRISPR-based therapy that affects reproduction. The lawsuit targets HHS and its Office of the Inspector General.
Eli Lilly’s Alzheimer’s Drug Obtains FDA Approval. Here’s Why the Stock Isn’t Taking Off.
July 13, 2024 / Eli Lilly / Alzheimer’s / Drug Approval / FDA Approval / Stock Preformance
Eli Lilly’s Alzheimer’s drug, Kisunla, received FDA approval, but the stock didn’t surge because the approval was anticipated and already factored into the stock’s valuation. Investors are more focused on Eli Lilly’s promising GLP-1 treatments for obesity and diabetes.
FDA’s lab-developed test rule could be first test of agency’s power post-Chevron
July 11, 2024 / FDA / Chevron / Supreme Court
The FDA’s new rule on lab-developed tests (LDTs) could face challenges after the Supreme Court’s Chevron decision, which limits agency deference. This rule expands FDA oversight of LDTs, requiring compliance with medical device regulations.
On track to squeeze FDA budget, Congress still makes detailed demands of agency
July 12, 2024 / FDA / Budget Cuts / Funding / Biden
Congressional committees voted to allocate $3.5 billion to the FDA for FY25, cutting $22 million from the previous year and falling $182 million short of the Biden administration’s request. This budget cut could impact FDA’s staffing, morale, and oversight activities.
// Research & Development
Revolution Medicines firms up Phase 3 trial plans with latest cancer drug data
July 15, 2024 / Pancreatic Cancer Drug Trial / Cancer Treatment / Mutation Therapy
Revolution Medicines’ experimental drug RMC-6236 showed promising results in shrinking pancreatic tumors in about 25% of participants with RAS mutations, leading to a median progression-free survival of 8.1 months. The drug will advance to a Phase 3 trial later this year.
Positive Data in Pancreatic Cancer Pave Way for Pivotal Test of Revolution Medicines Drug
July 15, 2024 / Revolution Medicines / Clinical Trials / Mutation Therapy
Revolution Medicines’ experimental drug RMC-6236 showed promising early-stage results in treating pancreatic ductal adenocarcinoma (PDAC), leading to a median progression-free survival of 8.1 months. The company plans to initiate a pivotal Phase 3 trial later this year.
Lexeo’s Gene Therapy Shows Early Promise for Friedreich’s Ataxia Cardiomyopathy
July 15, 2024 / Leexeo Therapeutics / Gene Therapy / Cardiac Hypertrophy Reduction
Lexeo Therapeutics’ investigational gene therapy, LX2006, showed significant reductions in cardiac hypertrophy and improvements in key biomarkers in patients with Friedreich’s ataxia cardiomyopathy in interim Phase I/II data. The therapy was well-tolerated with no serious adverse events reported.
Ozempic Tied to Lower Risk of Dementia, Nicotine Misuse: Study
July 15, 2024 / Ozempic / Dementia Risk / Semaglutide / GLP-1
A study found that Novo Nordisk’s Ozempic (semaglutide) is associated with a lower risk of dementia and nicotine misuse. Although observational, the study suggests potential neuropsychiatric benefits, prompting further investigation into Ozempic’s broader therapeutic applications.
Biotech pioneer enhances access to innovative cancer treatments
July 15, 2024 / BeiGene / Cancer Treatments / Oncology / Clinicall Trials
BeiGene enhances access to innovative cancer treatments by conducting global in-house clinical trials, reducing costs and speeding drug development. Its new U.S. facility will expand production and R&D capabilities, supporting broader global access to affordable cancer therapies.
// Politics
Senator Warner urges HHS to end voluntary cybersecurity requirements
July 15, 2024 / Cybersecurity / Healthcare / Data Protection
Senator Mark Warner urged HHS to establish mandatory cybersecurity standards for healthcare, highlighting the sector’s vulnerability to attacks and the insufficiency of voluntary measures. He stressed that inadequate cybersecurity endangers patients and disrupts healthcare operations.
Novo Nordisk faces scrutiny on Capitol Hill for pulling Levemir insulin from US market
July 15, 2024 / Novo Nordisk / US Senate / Insulin / Drug Price / Diabetes
Novo Nordisk faces Senate scrutiny for discontinuing Levemir insulin in the U.S. Democratic senators are concerned about the impact on diabetes patients, though Novo cites manufacturing constraints and alternatives like Tresiba. The company faces ongoing pressure to reduce drug prices.
What to know about Trump VP pick J.D. Vance’s health care views and investments
July 15, 2024 / JD Vance / Trump / Healthcare
Sen. J.D. Vance, chosen as Trump’s running mate, has invested in biotech startups, drug discovery firms, health data companies, and health tech platforms. His healthcare policies sometimes diverge from his party’s base.
Samsung participates in US biotech company’s $277 million investment
July 11, 2024 / Samsung / Healthcare / Investment / Element Biosciences
Samsung Electronics participated in a $277 million Series D investment round for Element Biosciences, a U.S. biotech company. This strategic investment aims to create synergy in the medical and digital healthcare sectors.
Pharma companies against plan to bring nutraceuticals under drug regulator
July 17, 2024 / Drug Authority / Market Growth / FSSAI
Pharma companies oppose the plan to regulate nutraceuticals under the drug authority instead of the Food Safety and Standards Authority of India (FSSAI). They argue that current FSSAI regulations align with global standards and ensure product safety.